Loading stock data…
NTRB
$3.86-0.01 (-0.13%)
Market ClosedLast close May 1
Nutriband Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Nutriband Inc. in the Healthcare sector is trading at $3.86. The stock is currently near its 52-week low of $3.42, remaining 29.6% below its 200-day moving average. Technical signals show neutral RSI of 44 and bearish MACD signal, explaining why NTRB maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 44) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$3.86
Potential Upside
5%
Whystock Fair Value$4.05
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus1 analysts
Mean target$15.00+288.6%
Range$15.00 – $15.00
Fundamentals
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$50.77M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.93
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-169.27%
Volume
Today's trading volume
3,994
Recent News
The past five years for Nutriband (NASDAQ:NTRB) investors has not been profitable
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We don't wish...
Nutriband says ‘committed’ to shareholder value as ‘number one focus’
Nutriband (NTRB) announced that CEO Gareth Sheridan has published a letter to shareholders providing insights on achievements and milestones through 2025 and the potential outlook for 2026. The letter read, in part, “As we wrapped up a successful 2025, the entire team at Nutriband would like to extend our warmest appreciation to all of you for your continued support throughout 2025 and into 2026. I always stress and extend our appreciation to the many of you that have been with us from the begin
MediWound (MDWD) Reports Q3 Loss, Misses Revenue Estimates
MediWound (MDWD) delivered earnings and revenue surprises of +70.37% and -15.52%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
TELA Bio, Inc. (TELA) Reports Q3 Loss, Misses Revenue Estimates
TELA Bio (TELA) delivered earnings and revenue surprises of -11.76% and -5.53%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Korro Bio, Inc. (KRRO) Reports Q3 Loss, Lags Revenue Estimates
Korro Bio, Inc. (KRRO) delivered earnings and revenue surprises of +26.44% and -27.33%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?